CHENGDU, China, Sept. 28, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ('HitGen', SSE: 688222.SH) today announced that it has entered into a partnership with The Structural Genomics Consortium ('SGC'), a public-private partnership that supports the discovery of new medicines through open-access research. HitGen will utilize its DNA-encoded library (DEL) technology platform, specifically OpenDEL™, to screen under-represented targets chosen by SGC.

中国成都，2023年9月28日/PRNewswire/-上海证券交易所上市公司HitGen Inc.（'HitGen'，SSE:688222.SH）今天宣布已与Structural Genomics Consortium建立合作关系（'SGC'），这是一家公私合作伙伴关系，通过开放获取研究支持新药的发现。HitGen将利用其DNA编码库（DEL）技术平台，特别是OpenDEL™, 筛选SGC选择的代表性不足的目标。

The screening datasets, curated in a ML-ready format, will be posted to a publicly accessible portal to facilitate drug discovery and ML experts from around the world to model the data and make predictions about new active molecules that would be experimentally tested at SGC as part of the Target 2035 initiative. .

以ML-ready格式策划的筛选数据集将发布到可公开访问的门户网站，以促进来自世界各地的药物发现和ML专家对数据进行建模，并对将在SGC进行实验测试的新活性分子进行预测作为Target 2035倡议的一部分。 .

HitGen is a world leader in the development of DEL technology and applications to early-stage small molecule drug discovery. Its platform includes over 1.2 trillion small molecules generated by the DEL technology, and the efficiency of the screening process has made it possible for HitGen to enable drug discovery projects for many organizations around the world..

HitGen是DEL技术开发和早期小分子药物发现应用的世界领先者。它的平台包括DEL技术产生的超过1.2万亿个小分子，筛选过程的效率使HitGen能够为世界各地的许多组织启用药物发现项目。。

OpenDEL™ is a self-service DEL kit with over 3 billion compounds, which enables users to explore DEL selection campaigns without revealing the target identity. Under the guidance of the manual and operating instructions, users can utilize OpenDEL™ to conduct affinity screening experiments against protein targets in their own laboratories.

OpenDEL™ 是一个拥有超过30亿种化合物的自助DEL套件，使用户能够在不揭示目标身份的情况下探索DEL选择活动。在手册和操作说明的指导下，用户可以使用OpenDEL™ 在自己的实验室中对蛋白质靶标进行亲和筛选实验。

HitGen can provide upstream and downstream technical support..

HitGen可以提供上游或下游技术支持。。

'We look forward to working with the research teams at SGC to generate novel starting points for under-studied proteins and to place ML-ready representations of the data into the public domain on an open access basis. As one of HitGen's four core technology platforms, our world-leading DEL platform is an efficient 'engine' to advance drug discovery and has enabled hit identification and lead generation for many innovative discovery programs by our customers and partners.

“我们期待与SGC的研究团队合作，为研究不足的蛋白质创造新的起点，并在开放获取的基础上将ML就绪的数据表示放入公共领域。作为HitGen的四大核心技术平台之一，我们世界领先的DEL平台是推动药物发现的高效“引擎”，并为我们的客户和合作伙伴提供了许多创新发现计划的命中识别和铅生成。

We look forward to delivering useful starting points for targets chosen by SGC,' said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen Inc..

HitGen Inc.董事会主席兼首席执行官Jin Li博士说，我们期待为SGC选择的目标提供有用的起点。。

'I am confident that this partnership has the potential to be transformative,' said Aled Edwards, Chief Executive of the SGC, 'We look forward to providing the ML community with high-quality, well-curated data so they can contribute to our global effort to find drug starting points for all human proteins.'.

“我相信这种合作关系有可能具有变革性，”SGC首席执行官Aled Edwards说，“我们期待为ML社区提供高质量，精心策划的数据，以便他们能够为我们的全球做出贡献努力为所有人类蛋白质寻找药物起点“。

About HitGen Inc.HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD).

关于HitGen Inc.HitGen Inc.（SSE:688222.SH），是一家药物发现研究公司，总部位于中国成都，子公司位于英国剑桥和美国休斯顿.HitGen建立了领先的技术平台，使发现和优化小分子和核酸药物。我们的关键技术平台包括世界领先的DNA编码库技术（DEL），基于片段的药物发现和基于结构的药物设计技术（FBDD/SBDD），以及合成治疗性寡核苷酸技术的新兴技术平台（STO），和靶向蛋白质降解技术（TPD）。

Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage..

通过我们多样化灵活的商业模式，我们与全球数百家生物制药研究机构建立了合作伙伴关系。HitGen有从早期发现到临床试验阶段的多个项目。。

For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.For media inquiries: [email protected] For investor inquiries: [email protected]  For business development: [email protected]

欲了解更多信息，请致电+86-28-85197385，+1-508-840-9646或访问www.hitgen.com。进行媒体查询：[电子邮件保护]进行投资者查询：[电子邮件保护]用于商业发展：[电子邮件保护]

About the Structural Genomics Consortium

关于结构基因组学联盟

The Structural Genomics Consortium is a global public-private partnership that seeks to accelerate drug discovery by fostering collaboration among a large network of scientists in academia and industry and making all research outputs openly available to the scientific community. The current SGC research sites are located at Goethe University in Frankfurt, Karolinska Institute, McGill University, University College, London, the University of North Carolina, Chapel Hill, and the University of Toronto..

结构基因组学联盟是一个全球公私合作伙伴关系，旨在通过促进学术界和工业界大型科学家网络之间的合作并使所有研究成果向科学界公开提供来加速药物发现。目前的SGC研究地点位于法兰克福歌德大学，卡罗林斯卡研究所，麦吉尔大学，伦敦大学学院，北卡罗来纳大学教堂山分校和多伦多大学。。

For more information, contact Sofia Melliou: [email protected]

欲了解更多信息，请联系Sofia Melliou:[电子邮件保护]

SOURCE HitGen Inc.

来源HitGen Inc。